1416-P: Differences in Treatment and Metabolic Outcome between Males and Females Living with T2D—Results from the Multicenter DPV Registry

Abstract

To explore sex differences in diabetes therapy, outcome, and complications of adults with T2D in Germany. We included 77,587 individuals ≥18 years and ≥1 year of T2D duration that were treated between January 2019 and June 2022. Data was aggregated over the most recent treatment year and most recent diabetes therapy was evaluated. Age and diabetes duration-adjusted regression models are presented as estimated means with standard error mean. Median age was 71.1 [61.3 - 80.0] years, diabetes duration 11.5 [6.3 - 19.7] years, 55% male. Male patients were more often treated with insulin or OADs (51.3% vs. 50.5%, 28.1% vs. 26.5%, resp.). There were no sex differences in GLP1-RA treatment (male: 9.8%, female: 9.4%). SGLT2i treatment was significantly more frequent in males (18.4% vs. 12.2%). Females had a lower HbA1c compared with males, but a higher BMI. Dyslipidemia was more frequent in females compared with males, while hypertension was higher in males. We observed sex differences in treatment, especially newer OADs and GLP1-RA, metabolic control, and complications in all analyzed age groups. While women seem to be more affected by higher BMI and dyslipidemia, their metabolic control is better compared with males, although they have less medical treatment. Sex differences in compliance, adherence or disease perception could be the cause of these differences. Disclosure S.R.Tittel: None. G.Hess: Other Relationship; Novo Nordisk. S.Muehldorfer: None. A.Gillessen: None. R.Jung: Advisory Panel; Boehringer Ingelheim Inc., Speaker's Bureau; Novo Nordisk. M.D.Karl: None. S.Lanzinger: None.